William Blair & Company’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$290M Sell
1,334,109
-3,352
-0.3% -$744K 0.83% 23
2025
Q4
$306M Buy
1,337,461
+73,880
+6% +$16.8M 0.82% 23
2025
Q3
$293M Buy
1,263,581
+6,169
+0.5% +$1.26M 0.78% 26
2025
Q2
$233M Buy
1,257,412
+14,307
+1% +$2.66M 0.65% 39
2025
Q1
$260M Buy
1,243,105
+41,998
+3% +$8.16M 0.79% 26
2024
Q4
$213M Buy
1,201,107
+29,771
+3% +$5.47M 0.62% 43
2024
Q3
$231M Buy
1,171,336
+5,121
+0.4% +$956K 0.68% 34
2024
Q2
$200M Buy
1,166,215
+28,273
+2% +$4.68M 0.62% 41
2024
Q1
$207M Buy
1,137,942
+81,141
+8% +$14M 0.65% 37
2023
Q4
$164M Sell
1,056,801
-13,140
-1% -$1.92M 0.56% 45
2023
Q3
$159M Sell
1,069,941
-12,596
-1% -$1.85M 0.61% 39
2023
Q2
$146M Sell
1,082,537
-73,092
-6% -$10.7M 0.53% 43
2023
Q1
$184M Sell
1,155,629
-11,456
-1% -$1.75M 0.74% 31
2022
Q4
$189M Sell
1,167,085
-31,282
-3% -$4.8M 0.82% 28
2022
Q3
$161M Buy
1,198,367
+12,066
+1% +$1.73M 0.74% 32
2022
Q2
$182M Sell
1,186,301
-10,982
-0.9% -$1.68M 0.81% 26
2022
Q1
$194M Sell
1,197,283
-336
-0% -$48.8K 0.68% 31
2021
Q4
$162M Buy
1,197,619
+83,386
+7% +$9.85M 0.51% 44
2021
Q3
$120M Sell
1,114,233
-80,055
-7% -$9.15M 0.41% 54
2021
Q2
$135M Sell
1,194,288
-23,935
-2% -$2.7M 0.47% 47
2021
Q1
$132M Buy
1,218,223
+10,726
+0.9% +$1.15M 0.5% 45
2020
Q4
$129M Buy
1,207,497
+73,096
+6% +$7.02M 0.47% 49
2020
Q3
$99.4M Buy
1,134,401
+110,846
+11% +$10.4M 0.42% 53
2020
Q2
$100M Buy
1,023,555
+94,490
+10% +$8.32M 0.48% 45
2020
Q1
$70.8M Buy
929,065
+33,851
+4% +$2.88M 0.44% 54
2019
Q4
$79.3M Buy
895,214
+69,365
+8% +$5.76M 0.41% 61
2019
Q3
$62.5M Buy
825,849
+33,158
+4% +$2.27M 0.36% 67
2019
Q2
$57.6M Buy
792,691
+14,194
+2% +$1.12M 0.33% 76
2019
Q1
$62.7M Sell
778,497
-23,757
-3% -$1.94M 0.38% 71
2018
Q4
$74M Sell
802,254
-365
-0% -$32.1K 0.54% 44
2018
Q3
$75.9M Buy
802,619
+18,223
+2% +$1.73M 0.47% 52
2018
Q2
$72.7M Sell
784,396
-15,217
-2% -$1.49M 0.49% 51
2018
Q1
$75.7M Sell
799,613
-23,002
-3% -$2.53M 0.54% 47
2017
Q4
$79.6M Buy
822,615
+8,163
+1% +$769K 0.54% 45
2017
Q3
$72.4M Buy
814,452
+17,840
+2% +$1.36M 0.54% 46
2017
Q2
$57.8M Buy
796,612
+38,894
+5% +$2.61M 0.43% 58
2017
Q1
$47.9M Buy
757,718
+26,381
+4% +$1.66M 0.39% 70
2016
Q4
$45.8M Sell
731,337
-21,499
-3% -$1.31M 0.41% 69
2016
Q3
$47.5M Sell
752,836
-51,603
-6% -$3.34M 0.42% 70
2016
Q2
$49.8M Sell
804,439
-4,406
-0.5% -$268K 0.46% 63
2016
Q1
$46.2M Buy
808,845
+84,122
+12% +$4.69M 0.43% 70
2015
Q4
$42.9M Sell
724,723
-90,914
-11% -$5.24M 0.4% 74
2015
Q3
$44.4M Sell
815,637
-22,377
-3% -$1.46M 0.38% 78
2015
Q2
$56.3M Buy
838,014
+78,765
+10% +$5.14M 0.08% 320
2015
Q1
$44.4M Sell
759,249
-31,257
-4% -$1.89M 0.07% 351
2014
Q4
$51.7M Buy
790,506
+11,662
+1% +$735K 0.08% 323
2014
Q3
$45M Sell
778,844
-7,828
-1% -$435K 0.08% 337
2014
Q2
$44.4M Buy
786,672
+24,932
+3% +$1.31M 0.07% 345
2014
Q1
$39.2M Sell
761,740
-20,008
-3% -$1.01M 0.06% 373
2013
Q4
$41.3M Sell
781,748
-48,921
-6% -$2.4M 0.07% 372
2013
Q3
$37.2M Buy
830,669
+5,121
+0.6% +$227K 0.07% 397
2013
Q2
$34.1M Buy
+825,548
New +$36.1M 0.07% 392

Other funds holding ABBV

William Blair & Company's ABBV Position: Q1 2026 in Review

William Blair & Company reduced its AbbVie (ABBV) stake by 0.25% in Q1 2026, selling an estimated $744K and leaving 1,334,109 shares worth $290M. The position accounts for 0.83% of the portfolio, ranked #23.

William Blair & Company first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $306M in Q4 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • William Blair & Company held 1,334,109 shares of AbbVie worth $290M as of Q1 2026.
  • William Blair & Company sold 3,352 AbbVie shares in Q1 2026, an estimated $744K.
  • AbbVie made up 0.83% of William Blair & Company's portfolio in Q1 2026, its #23 holding.
  • William Blair & Company first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • William Blair & Company's AbbVie position peaked at $306M in Q4 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.